| __timestamp | Bausch Health Companies Inc. | CymaBay Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2026300000 | 8185000 |
| Thursday, January 1, 2015 | 2682700000 | 8871000 |
| Friday, January 1, 2016 | 2810000000 | 9645000 |
| Sunday, January 1, 2017 | 2582000000 | 12387000 |
| Monday, January 1, 2018 | 2473000000 | 14381000 |
| Tuesday, January 1, 2019 | 2554000000 | 19238000 |
| Wednesday, January 1, 2020 | 2367000000 | 17425000 |
| Friday, January 1, 2021 | 2624000000 | 23040000 |
| Saturday, January 1, 2022 | 2625000000 | 25116000 |
| Sunday, January 1, 2023 | 2917000000 | 51953000 |
Unlocking the unknown
In the ever-evolving landscape of the pharmaceutical industry, operational costs play a pivotal role in shaping a company's financial health. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of CymaBay Therapeutics, Inc. and Bausch Health Companies Inc. from 2014 to 2023.
Bausch Health, a giant in the sector, consistently reported SG&A expenses averaging around $2.6 billion annually, with a notable peak in 2023 at approximately $2.9 billion. This represents a steady increase of about 44% over the decade. In contrast, CymaBay Therapeutics, a smaller player, saw its SG&A expenses grow from $8 million in 2014 to $52 million in 2023, marking a staggering increase of over 500%.
This stark contrast highlights the diverse financial strategies and growth trajectories within the industry, offering valuable insights for investors and stakeholders.
Comparing SG&A Expenses: Johnson & Johnson vs Bausch Health Companies Inc. Trends and Insights
Comparing SG&A Expenses: AstraZeneca PLC vs CymaBay Therapeutics, Inc. Trends and Insights
BeiGene, Ltd. vs CymaBay Therapeutics, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: United Therapeutics Corporation vs Bausch Health Companies Inc. Trends and Insights
Comparing SG&A Expenses: Jazz Pharmaceuticals plc vs Bausch Health Companies Inc. Trends and Insights
Madrigal Pharmaceuticals, Inc. vs Bausch Health Companies Inc.: SG&A Expense Trends
Alpine Immune Sciences, Inc. vs Bausch Health Companies Inc.: SG&A Expense Trends
CRISPR Therapeutics AG and Bausch Health Companies Inc.: SG&A Spending Patterns Compared
Bausch Health Companies Inc. vs Amicus Therapeutics, Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Bausch Health Companies Inc. and Xencor, Inc.
Bausch Health Companies Inc. or Evotec SE: Who Manages SG&A Costs Better?